Clinical Trials Browser

Phase 2 × Osteosarcoma × glembatumumab vedotin × Clear all

NCT02487979 2022-01-18

Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma

Phase 2 Completed

22 enrolled 15 charts

Osteosarcoma